Celltrion’s Remsima SC Biosimilar Starts Strong In EU5 Countries
New Study Follows Approval For IBD Indications Last Year
Executive Summary
Celltrion is capitalizing on the earlier strength of its intravenous Remsima formulation to make waves with its innovative subcutaneous version, according to the results of a new study sampling nearly 250 gastroenterologists in EU5 countries.
You may also be interested in...
Celltrion Files Subcutaneous Infliximab In US – As Standalone BLA
Celltrion is seeking US approval for its subcutaneous formulation of infliximab, marketed in other territories as Remsima SC. The product will be registered as a standalone biologic rather than a biosimilar.
Celltrion Says New Data Prove Remsima SC Is A ‘Biobetter’
Celltrion says new data show that its Remsima SC subcutaneous infliximab biosimilar produces “statistically greater improvements in clinical outcomes” for rheumatoid arthritis patients compared to intravenous infliximab.
Celltrion Juggles Biosimilar Market Share As It Shifts To Direct Marketing
Celltrion Healthcare was ultimately able to increase its revenue by 16.7%, with stronger growth expected in H2.